Danaher (NYSE:DHR) Given New $245.00 Price Target at JPMorgan Chase & Co.

Danaher (NYSE:DHR) had its price target trimmed by JPMorgan Chase & Co. from $275.00 to $245.00 in a report published on Wednesday morning,MarketScreener reports. The firm currently has an overweight rating on the conglomerate’s stock.

DHR has been the subject of several other research reports. TD Cowen reduced their price target on shares of Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a report on Wednesday. Argus set a $265.00 price target on shares of Danaher in a report on Wednesday, January 14th. Evercore cut their price objective on shares of Danaher from $254.00 to $225.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Wolfe Research cut their price objective on shares of Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $245.00 price objective on shares of Danaher in a research report on Tuesday. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.20.

Danaher Stock Down 5.4%

Danaher stock opened at $184.11 on Wednesday. The stock has a market capitalization of $130.30 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 2.64 and a beta of 0.95. Danaher has a twelve month low of $180.03 and a twelve month high of $242.80. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. The company has a 50 day moving average of $197.17 and a 200-day moving average of $214.35.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.96%. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.88 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. On average, equities research analysts anticipate that Danaher will post 8.39 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a $0.40 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s payout ratio is presently 30.95%.

Insider Activity at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the sale, the executive vice president owned 5,099 shares of the company’s stock, valued at $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Continuum Advisory LLC bought a new stake in Danaher during the first quarter worth $754,000. Tred Avon Family Wealth LLC raised its position in Danaher by 8.2% during the first quarter. Tred Avon Family Wealth LLC now owns 7,694 shares of the conglomerate’s stock worth $1,459,000 after acquiring an additional 585 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in Danaher by 133.6% during the first quarter. Pinnacle Bancorp Inc. now owns 341 shares of the conglomerate’s stock worth $65,000 after acquiring an additional 195 shares in the last quarter. Patton Fund Management Inc. acquired a new position in Danaher during the first quarter worth approximately $217,000. Finally, Red Door Wealth Management LLC raised its stake in Danaher by 5.3% in the first quarter. Red Door Wealth Management LLC now owns 3,185 shares of the conglomerate’s stock valued at $604,000 after buying an additional 159 shares during the period. 79.05% of the stock is owned by institutional investors.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and modestly higher FY outlook — Danaher reported $2.06 non‑GAAP EPS (above consensus) and raised FY2026 EPS guidance to $8.35–$8.55, which supports the stock’s fundamental earnings trajectory. Danaher Reports First Quarter 2026 Results
• Positive Sentiment: Bioprocessing and Life Sciences momentum — Management cited strong demand in bioprocessing and life‑sciences tools (double‑digit strength in some businesses), a key driver of beat‑and‑raise dynamics. Reuters: Danaher beats first-quarter profit estimates
• Positive Sentiment: Some analyst support remains — Evercore raised its target to $232 (outperform), indicating pockets of continued buy‑side confidence despite cuts elsewhere. Evercore raises Danaher target
• Neutral Sentiment: €2.98B senior notes offering — Danaher priced €3.0B of euro‑denominated senior notes across several maturities; proceeds boost liquidity (and may fund M&A like Masimo) but add long‑term debt. PR Newswire: Euro‑denominated senior notes offering
• Negative Sentiment: Revenue miss and Diagnostics softness — Revenue rose ~3.7% to $5.95B, below consensus; core revenue growth was modest and Diagnostics (Cepheid/respiratory) was a clear weak spot, which pressured sentiment despite the EPS beat. Yahoo Finance deep dive
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), amplifying near‑term selling pressure even though many retain buy/overweight stances. MarketScreener: JPMorgan target change
• Negative Sentiment: Acquisition/integration and insider selling concerns — Investors are parsing the planned Masimo acquisition and near‑term capital allocation; recent insider sales headlines add to the cautious tone. QuiverQuant analysis

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.